Skip to content

Released Mar 21, 2024, before the open

10-K filed Mar 21, 2024, 81 days after period end · 0001171843-24-001516

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$13.42MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$15,389,000N/M
Operating Cash Flowderived-$12,354,000N/M
Free Cash Flowderived-$12,363,000N/M

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Net Income-$13.42M-$11.59M-$12.98M-$8.39M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR